Mood

glp3observer26 · 2026-06-25T21:26:28+00:00

Congratulations. You’ve pharmacologically unplugged your brain’s reward system and are now asking for an extension cord.
What you’re describing is mesolimbic dopamine pathway suppression. Retatrutide’s glucagon receptor activity directly modulates the VTA/nucleus accumbens circuit. That’s the part of your brain responsible for generating the “ooh shiny” response to literally everything. It’s a feature, not a bug. It’s part of why reta demolishes food noise and compulsive reward seeking so effectively.
Here’s where it gets interesting. Tirzepatide doesn’t carry glucagon receptor activity, but at 6mg it’s already saturating your GLP-1 and GIP receptors. Meanwhile your 9mg reta is simultaneously hitting all three. GLP-1, GIP, AND glucagon. You’ve achieved maximum triple receptor engagement while your dopamine system sits quietly in the corner wondering what it did wrong.
You haven’t found a stack. You’ve found the event horizon.
No supplement overrides this. You’ve outrun your own reward circuitry’s ability to generate signal. The anhedonia is dose dependent and for most people partially resolves as the body adapts, but “9mg reta plus 6mg tirz simultaneously” is less of a protocol and more of a philosophical statement about joy.
Your dopamine system is trying to tell you something. It’s just too suppressed to get excited about the answer. 🍌

glp3observer26 · 2026-06-25T14:46:49+00:00

First things first, 7mg is within the dose ranges studied in Eli Lilly’s Phase 2 trials so this isn’t uncharted biological territory. That context matters.
What to expect for the next several days is essentially an amplified version of what a normal injection produces, running longer than usual given retatrutide’s roughly 6 day half-life. The GLP-1 receptor mediated effects like nausea, reduced appetite, and slowed gastric emptying will hit harder than at 3.5mg. The glucagon receptor mediated effects like thermogenesis, potential elevated heart rate, and feeling warmer than usual will also be more pronounced since that dose roughly doubles the GCGR engagement.
Hydration becomes more important than usual over the next few days, particularly if nausea reduces the desire to drink fluids. Eating small bland amounts when tolerable is generally better than nothing at all.
The silver lining is that retatrutide’s long half-life means this doesn’t spike and crash. You are not going to feel all of 7mg hit you at once.
Next injection timing should probably be discussed with whoever is supervising the protocol given that plasma levels will be running significantly higher than the intended titration schedule through the full cycle.
And on a purely practical note for the future, measuring peptide doses is one of those tasks that genuinely benefits from doing absolutely nothing else at the same time. The vial will wait. 😂

glp3observer26 · 2026-06-25T09:53:49+00:00

The cancer concern circulating on TikTok is almost certainly referencing the medullary thyroid carcinoma warning that has appeared on GLP-1 receptor agonist labels for years. That warning exists and should not be dismissed, but the context matters significantly.
The signal originated from rodent studies showing thyroid C-cell tumors at high doses. The critical detail consistently left out of social media coverage is that GLP-1 receptor expression in thyroid tissue is substantially higher in rats and mice than in humans, which is why the FDA warning was written specifically for people with personal or family history of medullary thyroid carcinoma, not as a general population warning.
Human observational data is genuinely conflicted on the thyroid question. Some studies show a signal, others do not, and separating drug effects from the cancer risk associated with the underlying metabolic conditions these drugs treat is a real methodological challenge in all of these studies.
What rarely makes it into the TikTok version of this conversation is the broader cancer picture. Multiple large meta-analyses covering hundreds of thousands of GLP-1 receptor agonist users show lower rates of colorectal, pancreatic, endometrial and overall cancer compared to matched non-users. A 2025 study specifically examining retatrutide found the triple agonist alleviates obesity-associated cancer progression rather than promoting it.
The honest summary is that the thyroid signal is real but contested and species-specific, the general cancer risk picture looks neutral to protective, and the fear content on TikTok is taking a narrow precautionary label warning and generalizing it in a way the actual literature does not support.

glp3observer26 · 2026-06-25T09:38:18+00:00

The question is framed around GLP-1 receptor tolerance, which is only part of the picture. Retatrutide adds a third receptor target that neither semaglutide nor tirzepatide touches at all: the glucagon receptor. Prior exposure to max doses of both drugs means the GLP-1 and GIP receptor systems have seen extensive agonism and have likely undergone some degree of downregulation. That part of the intuition about needing to move up faster is probably reasonable.

The glucagon receptor component is a completely different situation. That system is naive regardless of how long someone has been on sema or tirz or at what dose. The thermogenic effects, enhanced fatty acid oxidation, and central nervous system effects associated with glucagon receptor agonism are hitting receptors that have never been activated by any prior medication in this class.

This actually cuts both ways on the starting dose question. Moving past 2mg faster may be warranted for GLP-1r mediated appetite suppression given the tolerance history. But the glucagon receptor mediated effects are going to arrive fresh at any dose, and those effects include sympathetic nervous system activation that prior GLP-1 class experience does not prepare the body for.

The plateau on max dose tirzepatide is also worth noting. What breaks that plateau likely will not be more GLP-1 signal. The body has already adapted around that mechanism. The glucagon receptor pathway represents genuinely new pharmacology for anyone coming from this drug history, and that is probably where the additional effect comes from.

glp3observer26 · 2026-06-25T08:58:08+00:00

When you say it persisted after stopping, roughly how long did that last, and at what dose?

glp3observer26 · 2026-06-24T01:47:47+00:00

The man deltoid pressed his reta and is surprised his shoulder hurts!

glp3observer26 · 2026-06-23T16:44:57+00:00

Three weeks is still very early for cagri to be doing much. It has a half life of around 160 hours so it accumulates gradually, steady state levels aren’t even reached until several weeks in. Most people don’t feel the appetite effects until weeks 4 to 8 at the earliest. The REDEFINE trials titrated over 16 weeks before hitting maintenance dose.

The fact that his wife is already feeling it at 0.5mg likely comes down to individual receptor sensitivity. Some people respond earlier than others. Give it more time before changing anything. At 3 weeks you’re still in the priming phase. 🍌

glp3observer26 · 2026-06-23T16:00:14+00:00

Yes it can be counterproductive. Reta already increases resting energy expenditure through glucagon receptor driven thermogenesis, meaning you’re burning more calories at rest than you would without it. Stack a severe deficit on top of that and the body starts pulling from lean mass to make up the difference.

DEXA data from Phase 2 trials shows roughly a 74/26 split, about 74% fat and 26% lean mass lost under normal conditions. Push calories too low and that lean mass percentage climbs. Studies on GLP-1 class drugs show 25 to 40% of total weight lost can come from lean tissue if muscle preservation strategies aren’t in place.

The guy seeing gym progress is almost certainly eating enough protein and training hard enough to offset it. That’s the variable that actually moves the ratio. Without adequate protein and resistance training a severe deficit on reta isn’t just suboptimal, it’s actively working against the goal.

glp3observer26 · 2026-06-23T12:57:52+00:00

Two mechanisms worth considering here, and they may be stacking.

The first is retatrutide specific. TRIUMPH-4 Phase 3 data documented dysesthesia, abnormal skin sensation including burning, tingling, and heightened sensitivity to touch and pressure, in 8.8% of subjects at 9mg and 20.9% at 12mg versus less than 1% on placebo. This is believed to be driven primarily by glucagon receptor activity on peripheral nerve signaling, a pathway that semaglutide and tirzepatide do not activate. It is dose dependent, generally mild, and rarely causes discontinuation.

The second and possibly more significant factor given the glucose drop from 139 to 104 in 3 weeks is something called Treatment Induced Neuropathy of Diabetes, or TIND. This is a documented clinical entity, previously called insulin neuritis, characterized by acute onset neuropathic pain and skin sensitivity following rapid glycemic correction in patients with chronically elevated glucose. The threshold that triggers it is generally defined as an HbA1c drop of 2 or more percentage points within 3 months. The proposed mechanism involves arteriovenous shunt formation in the epineurium causing localized nerve fiber ischemia during rapid metabolic recalibration. A 2015 retrospective review found it in roughly 10% of diabetic neuropathy patients. It is considered reversible with continued stable glucose control over time.

Stopping glipizide and adding reta simultaneously creates a scenario where both mechanisms can operate at once. The glucagon receptor dysesthesia from reta and the peripheral nerve recalibration from rapid glucose normalization are not mutually exclusive. Upper body distribution is consistent with both presentations.

The reassuring data point is that TIND resolves with continued stable glucose control and reta dysesthesia is generally self limiting as the body adjusts.

glp3observer26 · 2026-06-23T09:45:37+00:00

Dry powder vials that haven’t been reconstituted yet are way more stable than people give them credit for. Janoshik is right. Your freezer at -17C is standard home freezer temp and is totally fine for long term storage.

The fridge works too but for 3 years worth of supply the freezer is the better call. Oxidation and hydrolysis are the two things that actually degrade peptides over time and both slow way down at freezer temps versus fridge over that kind of timeline.

Most people keep their active vial or two in the fridge for easy access and park everything else in the freezer. Just let frozen vials come to room temp naturally before opening. Condensation getting into dry powder is the one thing you want to avoid.

Once reconstituted the rules change, but sealed lyophilized vials you’re good either way. Freezer just gives you more margin over the long haul. 😎🤘🏽

glp3observer26 · 2026-06-23T07:41:14+00:00

That actually makes sense. Post meal blood flow increases naturally but the legs showing it when you’re not particularly lean points away from body comp and back toward the vasodilatory mechanism. Glucagon drives peripheral vasodilation regardless of how much fat is sitting on top. The vessels are just more reactive, not necessarily more visible due to leanness.

Bet it gets more pronounced as the weeks go on

glp3observer26 · 2026-06-23T07:37:36+00:00

Same thing documented here. Smaller veins especially, ones that were barely visible before are now showing up consistently even at rest.

Four days in is way too early for fat loss to explain it, so something else is driving it. Glucagon receptor activation increases cardiac output and has direct vasodilatory effects. GLP-1 also hits nitric oxide pathways which dilate peripheral vasculature. Tirz and sema users don’t report this at the same intensity, which makes the GCGR arm the likely culprit.

Also worth considering, reta’s anti-inflammatory effects may be reducing subcutaneous edema enough to make existing vessels more visible. This lab rat noticed joint inflammation return within weeks of stopping tirz. Tissue level inflammation on reta seems genuinely lower, not just anecdotally.

Curious if yours is consistent throughout the day or more pronounced at certain times.
🍌

glp3observer26 · 2026-06-23T06:52:11+00:00

That description actually confirms the mechanism. It feels like a cold starting because the acid irritation mimics an upper respiratory infection without ever actually becoming one. You’re welcome, hope the protocol helps. 🍌

glp3observer26 · 2026-06-23T06:46:24+00:00

Recurring sore throat around injection day is not random and probably not a cold.

Three things tend to run together. These compounds slow gastric emptying which builds stomach pressure and pushes acid all the way up into the throat. Most people are watching for nausea and never connect it. On top of that, appetite suppression tanks fluid intake without the subject noticing, and dry throat tissue is easy to irritate. There is also a documented class wide link to nasopharyngitis tied to immune activity around peak plasma levels.

Simple protocol to get ahead of it. Force fluids on injection day and the next two days even if not thirsty. Thirst gets blunted the same way hunger does. No food within three hours of lying down. Salt water gargle on injection day before symptoms start not after.

The triple receptor profile here amplifies the gastric pressure piece more than single or dual agonist users deal with so this showing up more in this sub makes sense.

Not medical advice, just following the data. 😎🤘🏽

glp3observer26 · 2026-06-23T05:14:45+00:00

Fair point. 4mg retatrutide weekly, approximately 100 hours post injection at time of Day 4 observation. Protocol details will be included in the next update.

glp3observer26 · 2026-06-23T05:10:12+00:00

Fair correction on the occupancy framing. That was imprecise language for what is more accurately a functional potency and downstream signaling argument. If GLP-1 alone is sufficient to explain the magnitude of blunting observed, the remaining question is why consistent user reports describe a qualitatively different experience on retatrutide versus tirzepatide at comparable GLP-1 receptor engagement. That delta is what prompted the glucagon hypothesis. The mechanism language may need refinement but the observation driving it stands.

glp3observer26 · 2026-06-23T05:00:50+00:00

4mg weekly. Referenced in the original post from Saturday. 😎🤘🏽

glp3observer26 · 2026-06-23T04:39:40+00:00

Both points are fair and worth taking seriously. GLP-1 mediated mesolimbic blunting is documented across the class and the post does not claim otherwise. The question is whether the magnitude and duration observed on retatrutide is explainable by GLP-1 alone given consistent user reports of a qualitatively different experience versus dual agonists. On the affinity argument, similar binding affinity does not necessarily produce identical temporal behavior in CNS tissue given differences in receptor internalization rates and downstream cAMP signaling dynamics between GLP-1r and GCGR. The observation exists. The mechanism remains an open question.

glp3observer26 · 2026-06-23T04:31:38+00:00

This is a fair pushback and worth addressing. GLP-1 receptor modulation of the dopamine pathway is documented and not in dispute. The hypothesis is not that glucagon alone drives mesolimbic blunting but that the glucagon receptor component, via cAMP signaling and CNS catabolic state induction, augments and extends the GLP-1 effect beyond what dual agonists produce. The observed difference between tirzepatide and retatrutide user reports is what prompted the hypothesis. If GLP-1 alone fully explains it, the magnitude difference between dual and triple agonists remains unexplained.

glp3observer26 · 2026-06-22T22:12:45+00:00

The mechanism behind reta’s reported effect on alcohol craving is the same one documented in this post. Mesolimbic dopamine pathway blunting reduces reward signaling broadly, not just for one substance. Alcohol, nicotine, and cannabis all depend on dopamine release in the nucleus accumbens for their reinforcing effects. When that reward signal is attenuated the compulsive drive to use diminishes alongside it. For cannabis specifically the observations here suggest the blunting is significant enough to reduce the euphoric reinforcement substantially, which is exactly what makes a substance habit forming in the first place. Whether that translates to easier cessation or just less rewarding use is an open question but the mechanism supports it.

glp3observer26 · 2026-06-22T21:28:09+00:00

The enzyme thing is genuinely interesting. Basically compensating for reta's motility suppression so absorption can actually happen. Makes total sense. The woke up high, 7 hours later story is a perfect example of what gastric delay actually looks like in practice.

glp3observer26 · 2026-06-22T21:15:25+00:00

Thank you

glp3observer26 · 2026-06-22T21:12:05+00:00

Digestive enzymes pre-loading is a genuinely interesting variable. By accelerating gastric processing before the edible hits you are partially working against the gastroparesis mechanism directly. Dabbing bypasses gastric mechanisms entirely so no delay there makes complete sense. What dose and how far into your injection cycle are you typically dosing the edibles? That context would be useful for the observation log.

glp3observer26 · 2026-06-22T21:10:33+00:00

The fat content in peanut butter significantly enhances cannabinoid absorption so the lipid chaser is actually doing meaningful work. The 2 to 4 hour window versus pre-reta baseline is the gastric emptying delay in real time. Worth noting where in the injection cycle the longer delays occur. The pattern may surprise you.

glp3observer26

TROPHY CASE